Lilly's dulaglutide outperforms widely used diabetes drugs in trials

06/24/2013 | Reuters

Three late-stage trials indicate that patients injected with Eli Lilly and Co.'s experimental GLP-1 receptor agonist dulaglutide experienced sustained reductions in blood sugar and lost more weight compared with patients who took generic metformin, Bristol-Myers Squibb's Byetta and Merck & Co.s' Januvia. Lilly plans to submit dulaglutide for U.S. approval this year.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX